Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. SCA Pharmaceuticals, Inc.
483
•SCA Pharmaceuticals, Inc.•October 20, 2025

SCA Pharmaceuticals, Inc. – FDA 483, Oct 20, 2025

Record Details

During an FDA inspection from October 20-30, 2025, SCA Pharmaceuticals, Inc., an outsourcing facility in Little Rock, AR, received an FDA Form 483 detailing four significant observations indicating non-compliance with current Good Manufacturing Practices (cGMP) for sterile drug products. Key issues included a lack of established procedures to prevent microbiological contamination, specifically insufficient monitoring of personnel directly engaging with sterile manufacturing environments during critical operations. The inspection also found deficiencies in aseptic processing area air supply, noting the absence of comprehensive airflow visualization studies in all Laminar Flow Hoods used for sterile production. Furthermore, the firm failed to thoroughly investigate microbial excursions recovered from ISO-classified areas before distributing product batches. Investigations prematurely concluded that contamination was limited to only portions of batches without sufficient supporting evidence, leading to the release of potentially impacted sterile products such as Ketamine HCI and Phenylephrine HCI syringes. Lastly, laboratory controls for product inspection and defect classification were deemed inadequate. The firm"s system inappropriately categorized critical defects, including particulates in drug solutions and foreign material within syringe stopper ribs, as minor. These issues could compromise product sterility and pose serious patient risks. SCA Pharmaceuticals must implement robust corrective actions to address these deficiencies and ensure adherence to federal drug manufacturing regulations.

Company
SCA Pharmaceuticals, Inc.
Inspection date
October 20, 2025
Product type
Drugs
Office
Dallas District Office
Person
  • Demario L. Walls (Investigator)
View Company Profile

ID · b241011e-ec18-43b3-ba69-6aae9c51750b

Other documents for SCA Pharmaceuticals, Inc.
  • 483 - 2023-05-17May 17, 2023
  • 483 - 2019-11-07November 7, 2019
  • 483 - 2017-09-29September 29, 2017
  • 483 - 2014-04-01April 1, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore SCA Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.